Drug Database
Back to search

Belgium· BE-AMP-SAM509431-00

Glyxambi 10 mg - 5 mg

A linagliptin and empagliflozin product containing empagliflozin, registered in Belgium by Boehringer Ingelheim International. The same ATC class is registered in 13 of our 19 countries.

ATC A10BD19

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedGlyxambi 10 mg - 5 mgATCA10BD19REGISTER NO.BE-AMP-SAM509431-00PACKS LISTED0CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about empagliflozinAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Linagliptin and empagliflozin is registered in 13 of 19 countries.

Countries holding a registration under ATC A10BD19 (linagliptin and empagliflozin), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search linagliptin and empagliflozin products by name

Linagliptin and empagliflozin · ATC A10BD19

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Empagliflozin
Manufacturer
Boehringer Ingelheim International
Country
Belgium (BE)
ATC code
A10BD19
ATC class
Linagliptin and empagliflozin
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Linagliptin and empagliflozin in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All linagliptin and empagliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Empagliflozin Denk, Empagliflozin Devatis
  • Bulgaria · Глузод, Емлигекса
  • Cyprus · Glusod
  • Czechia · Empagliflozin Polpharma, Empelic
  • Germany · Empagliflozin Devatis, Emprables
  • Denmark · Bifoglan, Elemio
  • Estonia · Glusod
  • Spain · Empagliflozina Aurovitas, Empagliflozina Kern Pharma
  • Finland · Empagliflozin Devatis, Empagliflozin Reddy
  • United Kingdom (Northern Ireland) · Empagliflozin, Empagliflozin G.L. Pharma
  • Greece · Elemio, Empagliflozin Pharmapath
  • Croatia · Glusod
  • Hungary · Empagliflozin Polpharma
  • Ireland · Empagliflozin Krka
  • Iceland · Empagliflozin Reddy, Empagliflozin Wh 10 Mg
  • Liechtenstein · Jardiance
  • Lithuania · Embeflyx, Emlygexa
  • Luxembourg · Empagliflozin Ab
  • Latvia · Embeflyx, Emlygexa
  • Malta · Empagliflozin Denk, Eprekavor
  • Netherlands · Empagliflozine Devatis, Empagliflozine Doc
  • Norway · Empagliflozin Devatis, Empagliflozin Reddy
  • Poland · Empelic
  • Portugal · Empagliflozina Aurobindo, Empagliflozina Aurovitas
  • Romania · Glusod
  • Sweden · Empagliflozin Devatis, Empagliflozin Labiana
  • Slovenia · Empagliflozin Krka, Glusod
  • Slovakia · Empagliflozin Polpharma, Glusod

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c17e8e1b-6931-4478-857d-0fdcd78a907f
GET /v1/drugs/c17e8e1b-6931-4478-857d-0fdcd78a907f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Glyxambi 10 mg - 5 mg",
  "name_fr": "Glyxambi 10 mg - 5 mg",
  "name_nl": "Glyxambi 10 mg - 5 mg",
  "amp_code": "SAM509431-00",
  "strengths": [
    "10.0000",
    "5.0000"
  ],
  "pack_count": 9,
  "substances": [
    "Empagliflozin",
    "Linagliptin",
    "Mannitol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Linagliptin and Empagliflozin",
  "authorisation_numbers": [
    "EU/1/16/1146/002",
    "EU/1/16/1146/001",
    "EU/1/16/1146/004",
    "EU/1/16/1146/003",
    "EU/1/16/1146/006",
    "EU/1/16/1146/005",
    "EU/1/16/1146/008",
    "EU/1/16/1146/007",
    "EU/1/16/1146/009"
  ]
}
API referenceMCP serverPlans

See everything about linagliptin and empagliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console